fb-pixelThe Latest in Financial & Business News - The Boston Globe Skip to main content

More Life Sciences Headlines

This Cambridge startup, bootstrapped by billionaires, is developing ‘neuro-tech’ wearables

The company is designing products based on “electric medicine,” an approach that redirects brain waves through non-invasive stimulation — using sound, light, touch, and electrical pulses.

A looming threat to Greater Boston’s biotech dominance, 700 miles away

Boston-based firms that build biomanufacturing space see big opportunity in Raleigh-Durham — posing a threat that a key pillar of our region’s economy could grow faster elsewhere.

Biogen plans to shut down its controversial Alzheimer’s drug Aduhelm

The controversial approval of the Alzheimer’s disease treatment in 2021 led to scrutiny and outrage.

Vertex says its experimental painkiller works as well as opioids for acute pain — without risk of addiction

The Boston-based drug maker plans to apply by the middle of the year to the FDA to approve the medicine, which, if approved, would represent the first new class of painkillers in decades.

Vaccines save lives and generate profits. Why is investment lagging?

Even with the historic effort to develop COVID-19 vaccines, drug makers developing new vaccines for infectious diseases received 3.4 percent of all venture capital raised for biopharma companies in the past 10 years, according to a BIO report.

Gene-editing treatment from Vertex and CRISPR cleared for second rare blood disorder

About five weeks after the Food and Drug Administration greenlighted Casgevy as a breakthrough treatment for sickle cell disease, the agency cleared it for a related condition: transfusion-dependent beta thalassemia.

For-profit biomedical institute, backed by billionaires, launches in Cambridge to speed drug discovery

The institute will be led by cofounder Stuart Schreiber, a Harvard scientist who was also one of the founders of the Broad Institute.

Sage CEO sees encouraging sales for new pill for postpartum depression

The pill, called Zurzuvae, has generated lots of interest among psychiatrists, OB-GYNs, and primary care physicians, the executive said.